Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 647-653

  Li, Weixing ^a   Escarpe, Paul A ^a   Eisenberg, Eugene J ^a   Cundy, Kenneth C ^a   Sweet, Clive ^b   Jakeman, Kenneth J ^b   Merson, James ^c   Lew, Willard ^a   Williams, Matt ^a   Zhang, Lijun ^a   Kim, Choung U ^a   Bischofberger, Norbert ^a   Chen, Ming S ^a   Mendel, Dirk B ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 3 (1 ETHYLPROPOXY) 5 GUANIDINO 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VIRUS REPLICATION;

EID: 0031916471     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.647     Document Type: Article

References (37)

1. Assaad, F., T. Bektimirov, and K. L. Esteves. 1984. Influenza - world experience, p. 5-38. In C. H. Stuart-Harris (ed.), The molecular virology and epidemiology of influenza. Academic Press, London.
2. Belshe, R. B., E. Burke, F. Newman, R. L. Cerruti, and I. S. Sim. 1989. Resistance of influenza A virus to amantidine and rimatidine: result of one decade of surveillance. J. Infect. Dis. 159:430-435.
3. Bergogne-Berezin, E. 1988. Pharmacokinetics of antibiotics in respiratory secretions, p. 608-631. In J. Pennington (ed.), Respiratory infections; diagnosis and management. Raven Press, New York, N. Y.
4. Burnet, F. M. 1948. Mucins and mucoids in relation to influenza virus action. Aust. J. Exp. Biol. Med. Sci. 26:381-387.
5. Couch, A. B. 1993. Advances in influenza virus vaccine research. Ann. N. Y. Acad. Sci. 685:803-812.
6. Eisenberg, E. J., A. Bidgood, and K. C. Cundy. 1997. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob. Agents Chemother. 41:1949-1952.
7. Hayden, F. G., and H. J. Hay. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantidine. Curr. Top. Microbiol. Immunol. 176:119-130.
8. Hayden, F. G., M. Lobo, J. J. Treanor, M. Miller, and R. G. Mills. 1997. Efficacy and tolerability of oral GS 4104 for early treatment of experimental influenza in humans, abstr. LB-26, p. 7. In 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Program Addendum. American Society for Microbiology, Washington, D.C.
9. Hayden, F. G., A. D. M. E. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N. Engl. J. Med. 337: 874-880.
10. Hayden, F. G., J. J. Treanor, A. F. Betts, M. Lobo, J. D. Esinhart, and E. K. Hussey. 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275:295-299.
11. Kim, C. U., N. Bischofberger, M. A. Williams, W. Lew, J. Merson, and C. Sweet. 1997. Efficacy of GS 4104 in ferrets infected with influenza A virus. Antivir. Res. 34:A74. (Abstract 114.)
12. Kim, C. U., W. Lew, M. A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M. S. Chen, D. B. Mendel, C. Y. Tai, W. G. Laver, and R. C. Stevens. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119:681-690.
13. Klenk, H.-D., and R. Rott. 1988. The molecular biology of influenza virus pathogenicity. Adv. Virus Res. 34:247-280.
14. Langmuir, A. D., T. D. Worthen, J. Solomon, C. G. Ray, and E. Peterson. 1985. Thucydides syndrome. A new hypothesis for the cause of the plague of Athens. N. Engl. J. Med. 313:1027-1030.
15. Laver, W. G., P. M. Colman, R. G. Webster, V. S. Hinshaw, and G. M. Air. 1984. Influenza virus neuraminidase with hemagglutinin activity. Virology 137:314-323.
16. Leinweber, F.-J. 1987. Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Dispos. 16:425-428.
17. Liu, C., M. C. Eichelberger, R. W. Compans, and G. M. Air. 1995. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69:1099-1106.
18. Lui, K. J., and A. P. Kendal. 1987. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 77:712-716.
19. Mendel, D. B., C. Y. Tai, P. Escarpe, W.-X. Li, C. U. Kim, M. A. Williams, W. Lew, L. Zhang, N. Bischofberger, J. H. Huffman, R. W. Sidwell, and M. S. Chen. 1997. GS 4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B viruses in vitro. Antivir. Res. 34: A73. (Abstract 111.)
20. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, J. Merson, S. A. Lacy, W. Lew, M. A. Williams, L. Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
21. 20a. National Institutes of Health. 1986. Guide for the care and use of laboratory animals. NIH publication 86-23. National Institutes of Health, Bethesda, Md.
22. Palese, P., and R. W. Compans. 1976. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 33:159-163.
23. Palese, P., K. Tobita, M. Ueda, and R. W. Compans. 1974. Characterization of temperature sensitive influenza virus mutants. Virology 61:397-410.
24. Potier, M., L. Mameli, M. Bélisle, L. Dallaire, and S. B. Melançon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acerylneuraminate) substrate. Anal. Biochem. 94:287-296.
25. Quon, C. Y., K. Mai, G. Patil, and H. F. Stampfli. 1988. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab. Dispos. 16:425-428.
26. Roerig, D. L., K. J. Kotrly, C. A. Dawson, S. B. Ahlf, J. F. Gualtieri, and J. P. Kampine. 1989. First-pass uptake of verapamil, diazepam, and thiopental in the human lung. Anesth. Analg. 69:461-466.
27. Ryan, D. M., J. Ticehurst, and M. H. Dempsey. 1995. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother. 39:2583-2584.
28. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
29. Sidwell, R. W., J. H. Huffman, D. L. Barnard, K. W. Bailey, M.-H. Wong, A. Morrison, T. Syndergaard, and C. U. Kim. 1997. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res., in press.
30. Smith, F. I., and P. Palese. 1989. Variation in influenza virus genes - Epidemiological, pathogenic, and evolutionary consequences, p. 319-359. In R. M. Krug, (ed.), The influenza viruses. Plenum, New York, N.Y.
31. Stella, V. J., W. N. A. Charman, and V. H. Naringrekar. 1985. Prodrugs: do they have advantages in clinical practice? Drugs 29:455-473.
32. 30a. Sweeny, D., et al. Unpublished results.
33. Taylor, G. 1990. The absorption and metabolism of xenobiotics in the lung. Adv. Drug Delivery Rev. 5:37-61.
34. von Itzstein, M., W.-Y. Wu, G. B. Kok, M. S. Pegg, J. C. Cyason, B. Jin, T. V. Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
35. von Itzstein, M., M. Wan Yang, and B. Jin. 1994. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor. Carbohydrate Res. 259:301-305.
36. Wood, N. D., M. Aitken, S. Sharp, and H. Evison. 1997. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers, abstr. A-123, p. 25. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
37. Woods, J. M., R. C. Bethell, J. A. V. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. M. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.